4D Molecular Therapeutics (FDMT) News Today $6.32 -0.16 (-2.47%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Sees Significant Growth in Short Interest4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 8,520,000 shares, an increase of 8.8% from the November 15th total of 7,830,000 shares. Based on an average trading volume of 894,400 shares, the short-interest ratio is currently 9.5 days.December 17 at 10:30 AM | marketbeat.com4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVSDecember 16 at 12:54 PM | finance.yahoo.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from AnalystsDecember 12, 2024 | americanbankingnews.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Moderate Buy" by AnalystsShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assiDecember 7, 2024 | marketbeat.comWalleye Capital LLC Takes $912,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Walleye Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 84,322 shares of the company's stock, valued at approximaDecember 7, 2024 | marketbeat.comRedmile Group LLC Increases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Redmile Group LLC raised its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 17.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,262,090 shares of the company's stock after buyDecember 5, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Holdings Trimmed by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund lessened its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 35.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 459,00November 30, 2024 | marketbeat.comBraidwell LP Buys 855,990 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Braidwell LP boosted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 231.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,225,448 shares of the company's stock after acquiringNovember 29, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In NowNovember 26, 2024 | insidermonkey.com4D Molecular initiated with an Underweight at Morgan StanleyNovember 21, 2024 | markets.businessinsider.com4D Molecular initiated by Morgan Stanley at underweightNovember 21, 2024 | msn.comCompetitive Pressures and Market Challenges Lead to Sell Rating on 4D Molecular TherapeuticsNovember 21, 2024 | markets.businessinsider.comMorgan Stanley Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Underweight RecommendationNovember 21, 2024 | msn.com4D Molecular Therapeutics (NASDAQ:FDMT) Earns Underweight Rating from Analysts at Morgan StanleyMorgan Stanley assumed coverage on shares of 4D Molecular Therapeutics in a research report on Thursday. They issued an "underweight" rating and a $8.00 target price for the company.November 21, 2024 | marketbeat.comHC Wainwright Has Negative Outlook for FDMT FY2024 Earnings4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Analysts at HC Wainwright reduced their FY2024 earnings per share estimates for 4D Molecular Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst M. Caufield now expects that the company will post earningNovember 18, 2024 | marketbeat.comFY2024 Earnings Forecast for FDMT Issued By Leerink Partnrs4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now expects that tNovember 18, 2024 | marketbeat.com4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNovember 15, 2024 | finanznachrichten.de4D Molecular Therapeutics: Strong Financial Position and Strategic Clinical Advancements Support Buy RatingNovember 15, 2024 | markets.businessinsider.comAnalyst Expectations For 4D Molecular Therapeutics's FutureNovember 14, 2024 | benzinga.comPromising Pipeline Developments and Expanding Opportunities Lead to Buy Rating for 4D Molecular TherapeuticsNovember 14, 2024 | markets.businessinsider.com4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNovember 14, 2024 | finance.yahoo.com4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNovember 13, 2024 | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Moderate Buy" by Brokerages4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eightNovember 12, 2024 | marketbeat.com4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach OutNovember 1, 2024 | stockhouse.comWe're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash WiselyOctober 31, 2024 | finance.yahoo.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Sees Significant Drop in Short Interest4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 9,490,000 shares, a decline of 13.2% from the September 30th total of 10,930,000 shares. Based on an average trading volume of 792,200 shares, the short-interest ratio is currently 12.0 days.October 29, 2024 | marketbeat.comNovo Holdings A S Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Novo Holdings A S increased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,500,000 shares of the company's stock after acquiring an additional 100,000 shares duOctober 27, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been given an average rating of "Moderate Buy" by the nine research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have giOctober 18, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock, Short Interest ReportOctober 15, 2024 | benzinga.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Quotes, Forecast and News SummaryOctober 15, 2024 | benzinga.comDimensional Fund Advisors LP Sells 216,250 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Dimensional Fund Advisors LP trimmed its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 532,742 shares of the comOctober 7, 2024 | marketbeat.com4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So SureOctober 4, 2024 | seekingalpha.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund raised its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 10.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 706,000 shares of the company'sOctober 4, 2024 | marketbeat.comMarshall Wace LLP Sells 71,880 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Marshall Wace LLP lowered its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 27.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 185,866 shares of the company's stock aftOctober 3, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. Expected to Post FY2024 Earnings of ($2.68) Per Share (NASDAQ:FDMT)4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Cantor Fitzgerald issued their FY2024 EPS estimates for shares of 4D Molecular Therapeutics in a report issued on Monday, September 23rd. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share oSeptember 25, 2024 | marketbeat.comCantor Fitzgerald Downgrades 4D Molecular Therapeutics (FDMT)September 24, 2024 | msn.comCantor Fitzgerald Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) to NeutralCantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday.September 23, 2024 | marketbeat.com4DMT Announces Presentation at the 2024 North American Cystic Fibrosis ConferenceSeptember 23, 2024 | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Buy" from AnalystsShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been given a consensus rating of "Buy" by the ten brokerages that are covering the firm, Marketbeat reports. Ten analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages thaSeptember 23, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Progyny (PGNY)September 19, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)September 19, 2024 | markets.businessinsider.com4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug CandidateSeptember 19, 2024 | finance.yahoo.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 14.4% 4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 14.4%September 19, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Given New $39.00 Price Target at Chardan CapitalChardan Capital boosted their price objective on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the stock a "buy" rating in a research note on Thursday.September 19, 2024 | marketbeat.com4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development DaySeptember 18, 2024 | globenewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading 4.2% Higher 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 4.2%September 18, 2024 | marketbeat.comKaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the FirmSeptember 17, 2024 | tmcnet.comSofinnova Investments Inc. Has $5.69 Million Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Sofinnova Investments Inc. lifted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 36.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 271,155 shares of the company's stock aSeptember 17, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Bought by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,413 shares of the comSeptember 15, 2024 | marketbeat.comFDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmSeptember 12, 2024 | businesswire.com Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now FDMT Media Mentions By Week FDMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.270.71▲Average Medical News Sentiment FDMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼43▲FDMT Articles Average Week Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CALT News SPRY News SNDX News ANIP News RCKT News BCYC News AVDL News SEPN News COLL News BCAX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FDMT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
